Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1991 Nov;50(Suppl 4):862–865. doi: 10.1136/ard.50.suppl_4.862

Major histocompatibility complex class II genes and systemic sclerosis.

D Briggs 1, K I Welsh 1
PMCID: PMC1033321  PMID: 1750798

Abstract

1. In no ethnic group is the overall association between systemic sclerosis and the MHC strong enough for direct clinical use. MHC associations do support the classification of the disease into limited cutaneous systemic sclerosis and diffuse cutaneous systemic sclerosis. 2. Indications are that associations between specific subsets of patients with systemic sclerosis and genetic markers will assume greater importance both diagnostically and prognostically. The group with lung fibrosis look prime candidates, for example. 3. Genetic markers are useful means of relating chemically induced systemic sclerosis like disorders with the classical disease. Vinyl chloride disease provides an example. 4. Evidence is emerging of strong associations between certain genetic markers and autoantibody production; a similar story has emerged in systemic lupus erythematosus. We believe that, eventually, genetic tests will be used to influence treatment in at least a subset of patients with systemic sclerosis but that a dramatic breakthrough will not be made until we know how the genetics of the disease relate to the primary biochemical disease characteristic--that is, the overproduction of collagen. In this respect it has been suggested that the 5' flanking DNA of dermal collagen genes is particularly susceptible to the action of Scl-70 (topoisomerase I). A problem is how to tie this and the other observations discussed above together. The association of autoantibodies with topoisomerase I provides a tentative link between the MHC and collagen gene expression. Although the role and reason for anti-Scl-70 in systemic sclerosis is unknown, humoral autoimmunity, at least in systemic lupus erythematosus, seems to be strongly dependent on specific HLA genes. With an understanding of the function of MHC products at the molecular level, HLA and disease associations can now be analysed on a mechanistic level. For insulin dependent diabetes mellitus it has been shown that the MHC determined susceptibility to the disease is conferred by neutral residues (Val, Ser, Ala), at position 57 of the DQ beta chain, while Asp at this position correlates with resistance. A similar phenomenon has been described in rheumatoid arthritis. Although DR4 in general is associated with rheumatoid arthritis, it is heterogeneous, but a subtype of DR4 which is characterised by positively charged residues at positions 70 and 71 of the beta chains is not found in patients with rheumatoid arthritis (Wordsworth B P et al, unpublished data). A similar approach applied to the study of systemic sclerosis is likely to be similarly rewarding. The precise subtyping of the class II genes and the characterisation of their associated haplotypes is therefore required for a complete understanding of the contribution of the MHC to the disease. Additional genes linked to the MHC must not be overlooked, and are relevant to associations of haplotypes with the disease. Of particular interest are the recent reports of a new class of proteins, which are determined by genes in the MHC and which are considered to play a part in the assembly of the antigen peptide/MHC molecule complex.

Full text

PDF
862

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnett F. C., Bias W. B., McLean R. H., Engel M., Duvic M., Goldstein R., Freni-Titulaer L., McKinley T. W., Hochberg M. C. Connective tissue disease in southeast Georgia. A community based study of immunogenetic markers and autoantibodies. J Rheumatol. 1990 Aug;17(8):1029–1035. [PubMed] [Google Scholar]
  2. Barnett A. J., Tait B. D., Barnett M. A., Toh B. H. T lymphocyte subset abnormalities and HLA antigens in scleroderma (systemic sclerosis). Clin Exp Immunol. 1989 Apr;76(1):24–29. [PMC free article] [PubMed] [Google Scholar]
  3. Bidwell J. DNA-RFLP analysis and genotyping of HLA-DR and DQ antigens. Immunol Today. 1988 Jan;9(1):18–23. doi: 10.1016/0167-5699(88)91351-5. [DOI] [PubMed] [Google Scholar]
  4. Bjorkman P. J., Saper M. A., Samraoui B., Bennett W. S., Strominger J. L., Wiley D. C. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature. 1987 Oct 8;329(6139):512–518. doi: 10.1038/329512a0. [DOI] [PubMed] [Google Scholar]
  5. Bjorkman P. J., Saper M. A., Samraoui B., Bennett W. S., Strominger J. L., Wiley D. C. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature. 1987 Oct 8;329(6139):512–518. doi: 10.1038/329512a0. [DOI] [PubMed] [Google Scholar]
  6. Black C. M., Welsh K. I., Maddison P. J., Jayson M. I., Bernstein R. M. HLA antigens, autoantibodies and clinical subsets in scleroderma. Br J Rheumatol. 1984 Nov;23(4):267–271. doi: 10.1093/rheumatology/23.4.267. [DOI] [PubMed] [Google Scholar]
  7. Black C. M., Welsh K. I., Walker A. E., Bernstein R. M., Catoggio L. J., McGregor A. R., Jones J. K. Genetic susceptibility to scleroderma-like syndrome induced by vinyl chloride. Lancet. 1983 Jan 1;1(8314-5):53–55. doi: 10.1016/s0140-6736(83)91578-7. [DOI] [PubMed] [Google Scholar]
  8. Briggs D. C., Vaughan R. W., Welsh K. I., Myers A., duBois R. M., Black C. M. Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet. 1991 Sep 14;338(8768):661–662. doi: 10.1016/0140-6736(91)91235-m. [DOI] [PubMed] [Google Scholar]
  9. Briggs D. C., Vaughan R. W., Welsh K. I., Myers A., duBois R. M., Black C. M. Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet. 1991 Sep 14;338(8768):661–662. doi: 10.1016/0140-6736(91)91235-m. [DOI] [PubMed] [Google Scholar]
  10. Brown J. H., Jardetzky T., Saper M. A., Samraoui B., Bjorkman P. J., Wiley D. C. A hypothetical model of the foreign antigen binding site of class II histocompatibility molecules. Nature. 1988 Apr 28;332(6167):845–850. doi: 10.1038/332845a0. [DOI] [PubMed] [Google Scholar]
  11. Brown J. H., Jardetzky T., Saper M. A., Samraoui B., Bjorkman P. J., Wiley D. C. A hypothetical model of the foreign antigen binding site of class II histocompatibility molecules. Nature. 1988 Apr 28;332(6167):845–850. doi: 10.1038/332845a0. [DOI] [PubMed] [Google Scholar]
  12. Bugawan T. L., Horn G. T., Long C. M., Mickelson E., Hansen J. A., Ferrara G. B., Angelini G., Erlich H. A. Analysis of HLA-DP allelic sequence polymorphism using the in vitro enzymatic DNA amplification of DP-alpha and DP-beta loci. J Immunol. 1988 Dec 1;141(11):4024–4030. [PubMed] [Google Scholar]
  13. Buus S., Sette A., Grey H. M. The interaction between protein-derived immunogenic peptides and Ia. Immunol Rev. 1987 Aug;98:115–141. doi: 10.1111/j.1600-065x.1987.tb00522.x. [DOI] [PubMed] [Google Scholar]
  14. Christy W. C., Rodnan G. P. Conjugal progressive systemic sclerosis (scleroderma): report of the disease in husband and wife. Arthritis Rheum. 1984 Oct;27(10):1180–1182. doi: 10.1002/art.1780271015. [DOI] [PubMed] [Google Scholar]
  15. Doherty D. G., Donaldson P. T. HLA-DRB and DQB typing by a combination of serology, restriction fragment length polymorphism analysis and oligonucleotide probing. Eur J Immunogenet. 1991 Feb-Apr;18(1-2):111–124. doi: 10.1111/j.1744-313x.1991.tb00011.x. [DOI] [PubMed] [Google Scholar]
  16. Douvas A. Does Sc1-70 modulate collagen production in systemic sclerosis? Lancet. 1988 Aug 27;2(8609):475–477. doi: 10.1016/s0140-6736(88)90122-5. [DOI] [PubMed] [Google Scholar]
  17. Dunckley H., Jazwinska E. C., Gatenby P. A., Serjeantson S. W. DNA-DR typing shows HLA-DRw11 RFLPs are increased in frequency in both progressive systemic sclerosis and CREST variants of scleroderma. Tissue Antigens. 1989 Mar;33(3):418–420. doi: 10.1111/j.1399-0039.1989.tb01686.x. [DOI] [PubMed] [Google Scholar]
  18. Dustoor M. M., McInerney M. M., Mazanec D. J., Cathcart M. K. Abnormal lymphocyte function in scleroderma: a study on identical twins. Clin Immunol Immunopathol. 1987 Jul;44(1):20–30. doi: 10.1016/0090-1229(87)90048-1. [DOI] [PubMed] [Google Scholar]
  19. Ercilla M. G., Arriaga F., Gratacós M. R., Coll J., Lecha V., Vives J., Castillo R. HLA antigens and scleroderma. Arch Dermatol Res. 1981;271(4):381–385. doi: 10.1007/BF00406682. [DOI] [PubMed] [Google Scholar]
  20. Genth E., Mierau R., Genetzky P., von Mühlen C. A., Kaufmann S., von Wilmowsky H., Meurer M., Krieg T., Pollmann H. J., Hartl P. W. Immunogenetic associations of scleroderma-related antinuclear antibodies. Arthritis Rheum. 1990 May;33(5):657–665. doi: 10.1002/art.1780330508. [DOI] [PubMed] [Google Scholar]
  21. Germain B. F., Espinoza L. R., Bergen L. L., Vagesh M., Vasey F. B. Increased prevalence of DRw3 in the CREST syndrome. Arthritis Rheum. 1981 Jun;24(6):857–859. doi: 10.1002/art.1780240615. [DOI] [PubMed] [Google Scholar]
  22. Gladman D. D., Keystone E. C., Baron M., Lee P., Cane D., Mervert H. Increased frequency of HLA-DR5 in scleroderma. Arthritis Rheum. 1981 Jun;24(6):854–856. doi: 10.1002/art.1780240614. [DOI] [PubMed] [Google Scholar]
  23. Kallenberg C. G., Van der Voort-Beelen J. M., D'Amaro J., The T. H. Increased frequency of B8/DR3 in scleroderma and association of the haplotype with impaired cellular immune response. Clin Exp Immunol. 1981 Mar;43(3):478–485. [PMC free article] [PubMed] [Google Scholar]
  24. Langdon N., Welsh K. I., van Dam M., Vaughan R. W., Parkes D. Genetic markers in narcolepsy. Lancet. 1984 Nov 24;2(8413):1178–1180. doi: 10.1016/s0140-6736(84)92742-9. [DOI] [PubMed] [Google Scholar]
  25. Livingston J. Z., Scott T. E., Wigley F. M., Anhalt G. J., Bias W. B., McLean R. H., Hochberg M. C. Systemic sclerosis (scleroderma): clinical, genetic, and serologic subsets. J Rheumatol. 1987 Jun;14(3):512–518. [PubMed] [Google Scholar]
  26. Luderschmidt C., Scholz S., Mehlhaff E., König G., Albert E. Association of progressive systemic scleroderma to several HLA-B and HLA-DR alleles. Arch Dermatol. 1987 Sep;123(9):1188–1191. [PubMed] [Google Scholar]
  27. Lynch C. J., Singh G., Whiteside T. L., Rodnan G. P., Medsger T. A., Jr, Rabin B. S. Histocompatibility antigens in progressive systemic sclerosis (PSS; scleroderma). J Clin Immunol. 1982 Oct;2(4):314–318. doi: 10.1007/BF00915073. [DOI] [PubMed] [Google Scholar]
  28. Maddison P. J., Skinner R. P., Pereira R. S., Black C. M., Ansell B. M., Jayson M. I., Rowell N. R., Welsh K. I. Antinuclear antibodies in the relatives and spouses of patients with systemic sclerosis. Ann Rheum Dis. 1986 Oct;45(10):793–799. doi: 10.1136/ard.45.10.793. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Marsh S. G., Bodmer J. G. HLA-DR and -DQ epitopes and monoclonal antibody specificity. Immunol Today. 1989 Sep;10(9):305–312. doi: 10.1016/0167-5699(89)90086-8. [DOI] [PubMed] [Google Scholar]
  30. McGregor A. R., Watson A., Yunis E., Pandey J. P., Takehara K., Tidwell J. T., Ruggieri A., Silver R. M., LeRoy E. C., Maricq H. R. Familial clustering of scleroderma spectrum disease. Am J Med. 1988 Jun;84(6):1023–1032. doi: 10.1016/0002-9343(88)90307-5. [DOI] [PubMed] [Google Scholar]
  31. Morrison L. A., Lukacher A. E., Braciale V. L., Fan D. P., Braciale T. J. Differences in antigen presentation to MHC class I-and class II-restricted influenza virus-specific cytolytic T lymphocyte clones. J Exp Med. 1986 Apr 1;163(4):903–921. doi: 10.1084/jem.163.4.903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Mullis K. B., Faloona F. A. Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. Methods Enzymol. 1987;155:335–350. doi: 10.1016/0076-6879(87)55023-6. [DOI] [PubMed] [Google Scholar]
  33. Májský A., Kobíková M., Stáva Z. HLA and scleroderma. Tissue Antigens. 1979 Oct;14(4):359–360. doi: 10.1111/j.1399-0039.1979.tb00862.x. [DOI] [PubMed] [Google Scholar]
  34. REES R. B., BENNETT J. Localized scleroderma in father and daughter. AMA Arch Derm Syphilol. 1953 Sep;68(3):360–360. [PubMed] [Google Scholar]
  35. Sasaki S., Yoshino H. Systemic scleroderma in mother and daughter. Arch Dermatol. 1977 Mar;113(3):378–379. doi: 10.1001/archderm.1977.01640030124033. [DOI] [PubMed] [Google Scholar]
  36. Sheldon W. B., Lurie D. P., Maricq H. R., Kahaleh M. B., DeLustro F. A., Gibofsky A., LeRoy E. C. Three siblings with scleroderma (systemic sclerosis) and two with Raynaud's phenomenon from a single kindred. Arthritis Rheum. 1981 May;24(5):668–676. doi: 10.1002/art.1780240507. [DOI] [PubMed] [Google Scholar]
  37. Singal D. P., Green D., Reid B., D'Souza M. Polymorphism of three HLA-DR3-bearing major histocompatibility complex extended haplotypes. Immunogenetics. 1989;29(4):277–280. doi: 10.1007/BF00717914. [DOI] [PubMed] [Google Scholar]
  38. Soppi E., Lehtonen A., Toivanen A. Familial progressive systemic sclerosis (scleroderma): immunological analysis of two patients and six siblings from a single kindred. Clin Exp Immunol. 1982 Nov;50(2):275–282. [PMC free article] [PubMed] [Google Scholar]
  39. Spies T., Bresnahan M., Bahram S., Arnold D., Blanck G., Mellins E., Pious D., DeMars R. A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway. Nature. 1990 Dec 20;348(6303):744–747. doi: 10.1038/348744a0. [DOI] [PubMed] [Google Scholar]
  40. Steen V. D., Powell D. L., Medsger T. A., Jr Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum. 1988 Feb;31(2):196–203. doi: 10.1002/art.1780310207. [DOI] [PubMed] [Google Scholar]
  41. Todd J. A., Bell J. I., McDevitt H. O. HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature. 1987 Oct 15;329(6140):599–604. doi: 10.1038/329599a0. [DOI] [PubMed] [Google Scholar]
  42. Trowsdale J., Hanson I., Mockridge I., Beck S., Townsend A., Kelly A. Sequences encoded in the class II region of the MHC related to the 'ABC' superfamily of transporters. Nature. 1990 Dec 20;348(6303):741–744. doi: 10.1038/348741a0. [DOI] [PubMed] [Google Scholar]
  43. Vaughan R. W., Lanchbury J. S., Marsh S. G., Hall M. A., Bodmer J. G., Welsh K. I. The application of oligonucleotide probes to HLA class II typing of the DRB sub-region. Tissue Antigens. 1990 Oct;36(4):149–155. doi: 10.1111/j.1399-0039.1990.tb01821.x. [DOI] [PubMed] [Google Scholar]
  44. Vicario J. L., Serrano-Rios M., San Andrés F., Arnaiz-Villena A. HLA-DR3, DR4 increase in chronic stage of Spanish oil disease. Lancet. 1982 Jan 30;1(8266):276–276. doi: 10.1016/s0140-6736(82)90994-1. [DOI] [PubMed] [Google Scholar]
  45. Welsh K. I., Briggs D. C. Genetic and environmental factors in scleroderma. Curr Opin Rheumatol. 1990 Dec;2(6):920–921. doi: 10.1097/00002281-199002060-00008. [DOI] [PubMed] [Google Scholar]
  46. Whiteside T. L., Medsger T. A., Jr, Rodnan G. P. HLA-DR antigens in progressive systemic sclerosis (scleroderma). J Rheumatol. 1983 Feb;10(1):128–131. [PubMed] [Google Scholar]
  47. Zinkernagel R. M., Doherty P. C. H-2 compatability requirement for T-cell-mediated lysis of target cells infected with lymphocytic choriomeningitis virus. Different cytotoxic T-cell specificities are associated with structures coded for in H-2K or H-2D;. J Exp Med. 1975 Jun 1;141(6):1427–1436. doi: 10.1084/jem.141.6.1427. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES